Aaron J. Kowalski

JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts.

JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY.

JDRF is an organization that collaborates with academic institutions, policymakers, and corporate partners to develop innovative therapies for people living with type 1 diabetes (T1D). The private company is based in Carmel. The American company is built on a grassroots model of people connecting in their local communities and collaborating regionally and globally for efficiency and broader fundraising impact. JDRF has invested over $2.20 billion in research funding since its inception and is dedicated to advocacy, community engagement, and their vision of a world without T1D.